View Article |
Bronchial asthma, hypertension and COVID-19: a case report
Nasronudin1, Nur Rosyid2, Brian Eka Rachman3, Purwaningsih4, Anna Surgean Veterini5, Brihastami Sawitri6.
Bronchial asthma is mentioned as a factor that worsens the condition of COVID-19 and vice versa. Hypertension is also comorbid that aggravates SARS-COV-2 infection. The aim of this case report is to present that bronchial asthma and hypertension may not worsen COVID-19 patients. We report a woman, 53 years old, positive swab RT-PCR result, comorbid uncontrolled hypertension, and partially controlled asthma. During treatment, there is anxiety, but bronchial asthma and hypertension can be controlled. Some of the drugs administered include antiviral favipiravir, systemic steroids, anti-IL-6 (tocilizumab), antihypertensives, bronchodilator inhalers, anti-anxiety, plasma convales- cence, anticoagulants, vitamins, and other anti-oxidants. Multidisciplinary management accelerates the improve- ment of the patient’s condition. Good bronchial asthma and hypertension management will control the patient’s condition and will not cause worsening during treatment due to COVID-19. Bronchial asthma and hypertension may not worsen COVID-19 if the therapy of COVID-19 and all comorbid can be controlled.
Affiliation:
- Universitas Airlangga Hospital, Indonesia
- Universitas Airlangga, Indonesia
- Universitas Airlangga, Indonesia
- Universitas Airlangga, Indonesia
- Universitas Airlangga, Indonesia
- Universitas Airlangga Hospital, Indonesia
|
|
Indexation |
Indexed by |
MyJurnal (2021) |
H-Index
|
3 |
Immediacy Index
|
0.000 |
Rank |
0 |
Indexed by |
Scopus 2020 |
Impact Factor
|
CiteScore (0.2) |
Rank |
Q4 (Medicine (all)) |
Additional Information |
SJR (0.144) |
|
|
|